AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAY 14 - (NewsRx.com & NewsRx.net) -- Xenova Group plc (NASDAQ: XNVA; London Stock Exchange: XEN) announced that patient dosing has begun in a Phase IIa cocaine administration trial for Xenova's therapeutic vaccine TA-CD, which is under development for the treatment of cocaine addiction.
The 10-patient, open label trial is being conducted in the United States and is designed to evaluate the effect of TA-CD on behavioral changes associated with cocaine administration.
Cocaine-dependent volunteers, specifically selected from those not seeking to quit, undergo psychological and physiological assessments while cocaine is administered under laboratory conditions. The effect of TA-CD will be determined by comparing findings from before and after a four-dose immunization course.
This study is being funded, in part, by the U.S. National Institute on Drug Abuse (NIDA). NIDA has also supported earlier clinical work on TA-CD. TA-CD is the first vaccine to be developed with the goal of assisting cocaine abusers in their attempt to quit cocaine.
Previous clinical studies have shown that administration of TA-CD leads to the generation of antibodies that can bind free cocaine. TA-CD is a cocaine derivative conjugated to a carrier protein and formulated with an adjuvant. ...